Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate.
PLoS Biol
; 11(11): e1001699, 2013 Nov.
Article
in En
| MEDLINE
| ID: mdl-24223516
ABSTRACT
The cost of whole genome sequencing is dropping rapidly. There has been a great deal of enthusiasm about the potential for this technological advance to transform clinical care. Given the interest and significant investment in genomics, this seems an ideal time to consider what the evidence tells us about potential benefits and harms, particularly in the context of health care policy. The scale and pace of adoption of this powerful new technology should be driven by clinical need, clinical evidence, and a commitment to put patients at the centre of health care policy.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sequence Analysis, DNA
/
Genomics
/
High-Throughput Nucleotide Sequencing
/
Health Policy
Type of study:
Health_economic_evaluation
/
Prognostic_studies
Limits:
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
PLoS Biol
Journal subject:
BIOLOGIA
Year:
2013
Document type:
Article
Affiliation country:
Canada